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Elementary osmotic pump (EOP) is a unique extended release (ER) drug delivery system
based on the principle of osmosis. It has the ability to minimize the amount of the drug,
accumulation and fluctuation in drug level during chronic uses. Carbamazepine (CBZ), a
poorly water-soluble antiepileptic drug, has serious side effects on overdoses and chronic
uses. The aim of the present study was to design a new EOP tablet of CBZ containing a
solubility enhancers and swellable polymer to reduce its side effects and enhance the
patient compliance. Firstly, a combination of solubilizing carriers was selected to improve
the dissolution of the slightly soluble drug. Then, designing the new EOP tablet and
investigating the effect of different variables of core and coat formulations on drug release
behavior by single parameter optimization and by Taguchi orthogonal design with analysis
of variance (ANOVA), respectively. The results showed that CBZ solubility was successfully
enhanced by a minimum amount of combined polyvinyl pyrrolidone (PVP K30) and sodium
lauryl sulfate (SLS). The plasticizer amount and molecular weight (MW) together with the
osmotic agent amount directly affect the release rate whereas the swellable polymer
amount and viscosity together with the semi-permeable membrane (SPM) thickness
inversely influence the release rate. In addition, the tendency of following zero order ki-
netics was mainly affected by the coat components rather than those of the core. Further,etpt@hotmail.fr (H. Rabti).
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0.1 mm to 0.8 mm. In this study we report the successful formulation of CBZ-EOP tablets,
which were similar to the marketed product Tegretol CR 200 and able to satisfy the USP
criterion limits and to deliver about 80% of CBZ at a rate of approximately zero order for up
to 12 h.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Oral delivery remains as the most preferable and convenient
route of administration for majority of drugs. Although they
provide a suitable balance of efficacy and safety with accept-
able clinical performance [1], conventional immediate release
(IR) dosage forms have severe adverse action due to dose
fluctuation and more importantly, low patient compliance
caused by frequent doses [2,3]. Therefore, the rationale for
development of an ER formulation of a drug is to improve the
patient compliancewith prescribed dosing regimens, enhance
the therapeutic effects, minimize the dose and hence the side
effects [1].
The osmotic pump tablet (OPT) is distinguished by utilizing
the osmotic pressure as energy source for drug release, and it
represents one of the most promising technologies for ER
delivery systems [4,5]. Thirty-one products have been devel-
oped and marketed based on osmotic technology and 161
patents were published on the formulation aspects of these
systems until the year 2000. In addition to being potentially
able to provide a constant release independently to the char-
acteristics of the release medium [4], these devices possesses
distinctive clinical benefits, such as minimizing the food-
effect and the improvement of the treatment tolerability and
patient compliance [6]. Various types of OPTs have been
developed and studied to deliver drugs with different aqueous
solubilities [7].
The convenience and simplicity to manufacture and eval-
uation, has contributed much to the popularity and
commercialization of EOPs over other osmotic based systems
[8]. They consist of a core, containing the active agent, an
osmogent and other excipients, coated with SPM. One orifice
is drilled in the SPM through which the drug is released after
the generation of osmotic pressure by the osmogent when
exposed to an aqueous environment [9]. EOPs are commonly
used to deliver water-soluble drugs but recently, some re-
searches had been carried out to enable the delivery of water-
insoluble drugs by EOPs [10]. Various attempts were utilized,
such as addition of a solubility modulating agent to the core
formulations [11], crystal-habit modifying agents for drugs,
like polymers, surfactants and/or wicking agents [12].
CBZ, a dibenzapine derivative, is widely used for the
treatment of epilepsy to control different types of seizures.
The drug absorption from IR dosage forms was slow and
erratic [13] and at overdoses and chronic use, CBZ exerts
serious side effects which signify the importance of its
incorporation into ER system. It also presents a poor aqueoussolubility which results into poor bioavailability after oral
administration [14]. Many previously published researches
have reported a successful improvement of CBZ solubility
using solid dispersion technique [13,15e17]. However, the use
of large amounts of polymer constitutes one of the major
drawbacks due to difficulties in handling and formulation into
a final dosage form especially for such high drug loading.
Further, in solid dispersion, maintaining the physical stability
of the drug and the vehicle still one of the major problems
together with the preparation technique and the difficulty in
up scaling [18].
Therefore, CBZ incorporation into an effective EOP delivery
system along with its solubility enhancement would improve
the bioavailability, reduce the side effects and avoid fluctua-
tion in plasma level [19].
In the present study, the development of a new design EOP
tablet for the poorly water-soluble drug (CBZ) by solubility
enhancement and incorporation of swellable polymer into the
core tablet, have been investigated and aimed to achieve an
optimum USP limit, zero order release, once daily adminis-
tration.Minimumamounts of a hydrophilic polymer (PVP K30)
and surfactant (SLS) were combined by simple physical mix-
ing and used as solubility promoter in order to prevent the
agglomeration of drug particles and increase their wettability.
Swellable polymer Hydroxypropyl methylcellulose (HPMC)
that was used in core formulations helps in formation of
uniform gel containing drug particles to be pushed out of the
device after water imbibitions and acts as another driving
force for drug release apart from osmotic pressure. The core
and SPM components were optimized using single parameter
analysis and Taguchi orthogonal array design (OAD), respec-
tively, including the type and amount of osmotic agent,
swellable polymer and plasticizer, SPM thickness and orifice
size. The effect of these factors on the release rate and kinetics
was discussed and the developed systems were statistically
compared with marketed ER CBZ tablets.2. Materials and methods
2.1. Materials
CBZ powder was purchased from Zhejiang Jiuzhou Pharma-
ceutical Co. Ltd. (Zhejiang, China). Cellulose acetate (CA,
opadry CA 500F 190001) and HPMC (E5, K100LV and K100M)
were from Shanghai Colorcon Coating Technology Ltd.
(Shanghai, China). PVP K30 was from ISP. (Shanghai, China).
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Fructose was from Shanghai Huixing Chemicals reagent Co.
Ltd. (Shanghai, China). Potassium chloride (KCl) was from
Shanghai Lingfeng Chemicals reagent Co. Ltd. (Shanghai,
China). SLS was from Shanghai Sinopharm Chemical reagent
Co. Ltd. (Shanghai, China). Polyethylene glycol (PEG) with MW
of 400, 1000 and 2000 kDa was from Shanghai Xilong Chem-
icals reagent Co. Ltd. (Shanghai, China). Commercial ER tab-
lets of CBZ (Tegretol CR 200 mg) were from Novartis
Pharmaceuticals Ltd. (Italy). All other chemicals and solvents
used were of analytical grade.
2.2. Methods
2.2.1. The CBZ solubilization by PVP K30 and SLS physical
mixtures
Physical mixtures (PMs) of CBZ with PVP K30 alone or in
combination with SLS were prepared in different ratios. The
blending process was carried out with constant trituration to
assure the uniform distribution of the drug among the addi-
tives. Subsequently, The resultant PMs were passed through
60-mesh sieve.
Solubility measurements of CBZ were performed as previ-
ously reported [20]. An excess amount (50 mg) of CBZ and PMs
of respective ratios was added to 10 ml of aqueous solutions.
The samples were sonicated for 1 h. Subsequently, they were
shaken at 37 C and 100 rpm for 48 h, filtered, suitably diluted
and their absorbance was noted at 284 nm in a double beam
UV/visible spectrophotometer (Rayleigh UV 9600, Beijing Ruili
Analysis Equipment Co. Ltd., China).
2.2.2. Core tablets preparation and optimization
Single parameter optimization was used to study the influ-
ence of different core formulation variables on drug release.
For the preparation of CBZ core tablets, all ingredients,
including predetermined amount of CBZ-PM, were accurately
weighed, passed through 60-mesh sieve, then well mixed by
hand mixing and directly compressed into tablets on 12 mm
concave punches under a pressure of 4e5 kg/cm2, using TDP
single Punch Tablet Press (Tianxiang Zhitai, Shanghai, China).
The amount of microcrystalline cellulose, filler, was varied to
fix each tablet weight at 660 mg (Table 1). After that, the coreTable 1 e The composition of CBZ core tablets.
Code Osmotic agent
(mg/each tablet)
Swellable polymer
(mg/each tablet)
Mannitol KCL Fructose E5 K100LV K100M
F1 200 50
F2 200 50
F3 200 50
F4 150 50
F5 250 50
F6 250 50
F7 250 50
F8 250 25
F9 250 75
Each core tablet contained 200 mg CBZ and the fixed ratio of PVP
K30 and SLS. The proper amount of magnesium stearate and talc
were added also.tablets were coated with CA (3% of weight gain) contained 40%
of PEG 400, and the release behavior was examined and
compared. The optimum formulation was selected to follow
zero order kinetics and to satisfy the USP 29 specification
limits for release rate from CBZ-ER tablet which were as fol-
lows; 3 h (10%e35%); 6 h (35%e65%); 12 h (65%e90%); 24 h
(>75%).
2.2.3. SPM preparation and optimization
Tablets were coated using spherical stainless steel pan coater
(Huanghai Medicine & Drug Testing Instruments Technology
Co. Ltd., Shanghai, China) with 3% (w/v) of CA dissolved in 90/
10 (v/v) of acetone/water under the following conditions; pan
rotating rate was 20 rpm; spray rate was 3 ml/min; drying was
achieved by a heat gun and the coat thickness was calculated
as the coating weight gain. Afterward, the coated tablets were
incubated at 40 C for 4 h in an oven to remove the residual
coating solvent and to complete the film formation. Finally,
one orifice was drilled on each coated tablet by laboratory
laser drilling apparatus (Nanjing Rui Ma Electronic Engineer-
ing Technology Co. Ltd., China).
A Taguchi OAD L9 was used for coating formulation opti-
mization. The four variables were selected as showed in
Table 2. L and subscript 9 denote the Latin square and the
number of the experimental runs, respectively. The run
involved the corresponding combination of levels to which
the factors in the experiment were set. All factors had three
levels and the drug release rate at 3, 6, 12 and 24 h, and drug
release kinetics were considered to be the responses variables.
The optimum responses were selected to follow zero order
kinetics and USP 29 specification limits described earlier.
2.2.4. In vitro release of CBZ from the prepared osmotic tablet
In vitro drug release studies were performed according to USP
29 specifications limits for CBZ-ER tablet, using the USP Type I
dissolution test apparatus (ZRS-8G dissolution tester, Tianda
Tianfa Technology Co. Ltd., China) at a basket speed of
100 rpmwith 900 ml of water as drug release medium for 24 h
at 37  0.5 C. 10 ml was withdrawn and replaced by the same
amount of fresh medium at 1, 3, 6, 9, 12 and 24 h. Samples
were filtered, suitably diluted and the absorbance was
measured at 284 nm. A comparative evaluation has been done
also with commercial ER tablets of CBZ (Tegretol CR 200). Drug
release profiles were drawn using MS-Excel software.
2.2.5. Release kinetics and statistical analysis
The data was treated with zero order, first order and Higuchi
equations (Eqs. (1), (2) and (3)) respectively [21].Table 2 e Factors and levels for OAD L9.
Factors Levels
1: low 2: medium 3: high
A: Plasticizer type PEG400 PEG1000 PEG2000
B: Plasticizer amount
(% CA)
20 40 60
C: SPM thickness
(% weight gain)
3 5 7
D: Orifice size (mm) 0.1 0.4 0.8
Table 3 e CBZ Solubility in different ratio of CBZ-PMs.
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(mg/ml)a
Pure CBZ CBZ 1 238.64  3.3
CBZ/PVP K30 PM1 1:0.5 300.49  2.7
CBZ/PVP K30/SLS PM2 1:0.4:0.1 410.45  2.9
CBZ/PVP K30/SLS PM3 1:0.3:0.2 519.84  3.6
a The values represent the Mean  SD (n ¼ 3).ln Qt ¼ ln Q0  K1t (2)
Qt ¼ KHt12 (3)
Where:
Qt is the cumulative amount of drug released at time (t) and
Q0 is the dose of the drug incorporated in the delivery system.
K0, K1 and KH are rate constant for zero order, first order and
Higuchi model, respectively.
R20, R
2
1 and R
2
H, square of release data for 12 h, fitted to zero
order, first order and Higuchi equations respectively, were
calculated and used to compare the release kinetics of
different formulations.
To introduce the release kinetics as response in the design,
we use the ratio between R20 to R
2
1 or R
2
H. If the result was more
than one, the release follows a zero order model. Otherwise, it
follows either first or Higuchi model.
The results of ANOVA for different batches of coated for-
mulations are calculated using Design-Expert version 8.0.6
software and they are statistically significant at p-value<0.05.
For further confirmation, the contribution percentage (PC %)
of each factor in the response was calculated using the
following equation [22]:
PC% ¼ SSP
SStotal
 100 (4)
Where SSp is the purified sum of squares and is given by SS-
Residual. SS is the individual sum of squares, Residual is the
sum of squares of error and SStotal is the total sum of squares.
The largest PC% value indicates themost significant influence
of the considered response.
The average response for each factor was computed at
each level and labeled as ki, where i represent a level.
In order to evaluate and compare dissolution data of the
optimized CBZ-EOP tablets and the marketed CBZ-ER tablets,
the dissolution profiles were statistically analyzed using
dissolution similarity factor f2 [23], calculated using the
following equation:
f2 ¼ 50$log
("
1þ 1
n
þ
Xn
t¼1
ðRt  TtÞ2
#0:5
 100
)
(5)
Where, n is numbers of dissolution time point
Rt is the reference dissolution point at time t
Tt is the Test dissolution point at time t
The f2 value between 50 and 100 suggest that the dissolu-
tion is similar. The f2 values of 100 suggest that the test and
reference profile are identical and as the value becomes
smaller, the dissimilarity between releases profile increases.3. Results and discussion
3.1. Solubility of CBZ in the physical mixture of PVP K30
and SLS
The CBZ solubility was found to be 238.64 mg/ml. As shown in
Table 3, CBZ in all PMs showed higher saturation solubility ascompared to pure one. Among various CBZ-PMs, PM2 and PM3
containing a combination of polymer and surfactant (PVP K30,
SLS) showed higher saturation solubility, whichwas increased
as the SLS fraction was raised in the PM. Although it is well
known that the PVP K30 will form a soluble complex with the
drug [16], it was evident that the amount of PVP K30 as used in
PM1 could not induce noticeable increase in CBZ solubility.
Since it reduces the surface tension of the drug particles, SLS
in combination with PVP K30 improves the wettability and
contributes to further solubility enhancement. Further, add-
ing small amounts of SLS (20e40 mg) inside the tablet core
were expected to locally increase the solubility of CBZ
whereas the same amount if added to the dissolution media
will not result in the same solubility enhancement. Therefore,
through the combining effects of solubility enhancement of
both PVP K30 and SLS we were able to formulate CBZ in EOP
tablets with improved release pattern. According to the above
studies, PM3 was used for the optimization of tablet core
formulation.3.2. Optimization of tablet core formulation
Parameters which were selected to optimize the core formu-
lations included the type and amount of both osmotic agent
and swellable polymer. The composition of each formulation
was shown in Table 1 and their release profiles were illus-
trated in Fig. 1 and Fig. 2.
3.2.1. Effect of type and amount of osmotic agent
It was reported that the drug release from osmotic tablets was
directly proportional to the difference in osmotic pressure
generated within the system [4]. Fig. 1A showed the release
profile of a formulation containing 200 mg of mannitol (F1),
KCl (F2) or fructose (F3) as osmotically active agents. Inter-
estingly, the highest release rate, about 68% at 24 h, with
highest R20 value (0.9882) was obtained with mannitol, which
has a lowest osmotic pressure (38 atm) as compared with KCl
(245 atm) and fructose (355 atm), whereas KCl exerted unex-
pected low release rate. These results might be explained by
the fact that KCl would be dissociated to Kþ and Cl and these
ions interacted or adsorbed to others ingredients in the core
tablet, the alkali cation (Kþ) would react with the SLS to form
insoluble crystals of potassium lauryl sulfate (KLS) [24].
Therefore the amount of KCl to induce the osmotic pressure of
the solution inside the tablets might be reduced and conse-
quently the rate of water flow into the tablet and the release of
drug reduced, since the driving force for the drug release in
this dosage form is the osmotic pressure. In addition, the
AB
Fig. 2 e Release profile from CBZ-EOP tablets containing
different polymer: (A) types and (B) concentrations,
(Mean ± SD, n [ 3).
A
B
Fig. 1 e Release profile from CBZ-EOP tablets containing
different osmotic agent: (A) types and (B) concentrations,
(Mean ± SD, n [ 3).
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overall release will be decreased.
On the other hand, when fructose was used as osmotic
agent, high and fast drug release in the first nine hours (48%)
was obtained, as comparing tomannitol (38%) andKCl (26%). It
was reported that drug release from osmotic devices continue
until the osmotic pressure between inside and outside envi-
ronment becomes equal [25]. Thus, we assume that cessation
of water/drugmovement across the SPMwas occurred (58% at
24 h) as a result of faster equilibrium in the osmotic pressure
created by fructose as compared to the other osmogents and
this is due to its highest osmotic pressure associated with its
concomitant release with the drug. Therefore mannitol was
chosen as osmogent for further investigation.
To study the influence of mannitol amount on CBZ
release rate, tablet core was prepared with different
amounts of mannitol. Fig. 1B illustrated that the release rate
of CBZ increased significantly with the increase of mannitol
amount from 150 to 250 mg with no effect on the release
kinetics which still follows zero order pattern. The more the
mannitol incorporated, the more water was imbibed and the
more the drug was released. Therefore the amount of
mannitol which was adopted for further investigation was
250 mg (F5).
3.2.2. Effect of type and amount of polymer
To examine the effect of polymer type on CBZ release,
different core formulations were prepared by using the same
amount, 50 mg per core tablet, of HPMC with different MW,
hence different viscosities; 5 cp, 100 cp and 100,000 cp for
HPMC E5, HPMC K100LV and HPMC K100M, respectively.
Fig. 2A showed that at 24 h the highest release rate, 70%, was
obtained by using HPMC of the highest viscosity, K100LV (F5),
whereas the lowest release rate, 57%, was obtained by the
lowest viscosity, E5 (F6). For the release kinetics, the highest
and the lowest viscosity HPMC obtained nearly similar values
of R20. These results indicate that the polymer type had no
significant effect on the release kinetics of CBZ from the pre-
pared formulations. HPMC of lowMW, such as E5, swelled and
dissolved quickly to give a solution of both low viscosity and
expanding force [8]. Therefore the driving force of drug release
form the device would be small. Whereas HPMC of a higher
MW swelledwell, increased the inner viscosity, the expanding
force and hence the drug release rate, as observed with F5.
However, if the MW of HPMC was greatly increased, such in
the case of HPMC K100M, the slower release was observed (F7)
due to the high viscosity of the system and the formation of
gel layer, which would obstruct the drug molecule diffusion.
Also it is previously reported that polymer with high viscosity
might close the drilled orifice and hindered the drug release
[8].
Fig. 2B showed that drug release rate increase by increasing
the polymer amount from 25 mg to 75 mg. High amount of
HPMC K100LV attains the appropriate viscosity and suitable
expanding force for the system. It was also observed that the
polymer amount did not affect the release kinetics as indi-
cated by the similarity of R20 values of all formulations. In
conclusion, apart from osmotic pressure, the polymer
swelling is another driving force for the drug release [8,26].
Therefore to get the required release profile, HPMC (K100LV) in
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 4 6e1 5 4 151the amount of 75 mg was used for further investigation of the
coating parameters.
3.3. Optimization of SPM formulations
To insure the ER properties of osmotic pump delivery system,
the core formulations are usually coated by semi-permeable
polymer coats. Parameters which were selected to optimize
the polymer coat included the type and amount of plasticizer,
coat thickness and orifice size. Table 4 showed the structure of
Taguchi OAD and the obtained results of drug release. The
average ki for the each studied factor was illustrated in Fig. 3
and the results of ANOVA analysis were tabulated in Table 5.
3.3.1. Effect of type and amount of plasticizer
When the CAeacetone solution is used alone for core coating,
the SPM will be ruptured easily during the drug release. Thus
in order to improve the SPM physical properties and film-
forming characteristics, plasticizers were usually incorpo-
rated into the coating solution [27]. As they can also affect the
permeability of the polymers films, it is important to investi-
gate their effects on drug release [8,28].
Fig. 3A showed that increase in PEG grade from 400 to
2000 lead to increase in drug release and its deviation from
zero order kinetics. The higher the PEG molecular weight,
the bigger the size of the formed pores after PEG leaching
[27], and hence the higher release rate and the more diffu-
sion obtained. Similar results were obtained in previous
study [29] where the drug release rate from enteric coated
microporous osmotic tablets was increased with the in-
crease in PEG grade. The result of ANOVA showed that the
PEG type is statistically significant and contributes to the
release rate. However, this effect is limited to the first 12 h
when the PEG is present in an effective concentration in the
tablet coat, after that the remaining amount will not
significantly contribute to the release. As expected the PEG
grade also contributed to the release kinetics by (PC%,
4.11%).
Fig. 3B showed that increase in PEG amountwould increase
the drug release rate and the deviation of the release profile to
Higuchi kinetics. Because of its hydrophilicity, PEG leaches
easily and can create a porous structure, which increases
membrane permeability and drug release rate [26]. The result
of ANOVA indicated that PEG amount was statistically sig-
nificant and represent the most influencing factor on both the
release rate and kinetics by its highest PC values as comparedTable 4 e Design matrix based on OAD L9 and measured respo
Run Factors
A B C D 3 h
1 2 3 1 2 29.1
2 3 1 3 2 2.76
3 3 2 1 3 20.4
4 2 1 2 3 1.39
5 3 3 2 1 22.5
6 1 1 1 1 2.69
7 2 2 3 1 8.90
8 1 3 3 3 10.9
9 1 2 2 2 5.70to other factors, so the optimization of plasticizer amount
could be considered as critical for the optimization of the
release behavior form the osmotic device.
3.3.2. Effect of SPM thickness
By separating the tablet inside from its outside, the SPM
represents a very important parameter in the osmotic device.
Fig. 3C showed that the drug release was inversely propor-
tional to the coat weight gain. This can be attributed to the
fact of increasing the SPM thickness will lead to increase its
resistance to imbibe the dissolution medium and lower the
dissolving rate of the tablet core components which conse-
quently reduces drug release rate from osmotic devices
[11,26]. The results of ANOVA indicated that this factor is
statistically significant during 12 h and beyond this time
point become less significant, however, the PC% indicates it
still have considerable contribution until 24 h. This study
revealed also that SPM thickness contributed to the release
kinetics by (PC%, 21.86%). Increase the SPM thickness will
reduce the drug diffusion by increasing the diffusional layer
thickness and hence lead to increase in the tendency of
following zero order kinetics. The SPM thickness is crucial to
provide the appropriate quantity of water in the tablet core in
the appropriate time and to assure that the pressure pro-
duced during swelling does not lead to rupture of the system
so its optimization is very important for approaching a
desirable release profile.
3.3.3. Effect of orifice size
Fig. 3D showed that there is no significant change in the
release parameters due to the change in orifice size from 0.1 to
0.8 mm. The results of ANOVA analysis indicated that this
factor is statistically insignificant (P > 0.05) and is not
contributing to the release rate and kinetics (PC, 0%). Similar
results were reported on osmotic devices of nifedipine [30],
naproxen [31] and indomethacin [8] in which there was no
significant difference in release rate of drugs from their os-
motic devices having the orifice size from 0.25 to 1.41, 1 to 1.5
and 0.35 to 0.55mm, respectively. However, it should be noted
that the orifice size has no effect on the drug release only
within certain range. Hydrostatic pressure could be developed
within the core if the orifice size is too small and solute
diffusion may occurred if it is too large [32]. It can be
concluded that in this study the orifice size plays no role in the
mechanism of drug release which was directed by other
formulation factors.nses.
Release rate (%) Release kinetics
6 h 12 h 24 h R20=ðR2H or R21Þ
46.2 86.85 93.2 0.9899
11.5 29.8 71.1 1.2418
47.5 78.5 97.3 0.9895
9.36 36.4 72.3 1.1991
43.02 82.8 92.3 0.9985
15.17 35.5 76.9 1.1918
21.9 40.2 81.9 1.1901
30.03 54.6 86.07 1.1348
22.7 50.2 80.8 1.1575
Fig. 3 e Average response at each level (ki) of: (A) plasticizer type, (B) plasticizer amount, (C) SPM thickness and (D) orifice size
for release rate and kinetics.
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The optimum formulation in which the core contains 60mg of
PVP K30, 40 mg of SLS, 250 mg of mannitol, 75 mg of HPMC
K100LV and coated with 3% of CA containing a 60% of PEG 400
with an orifice of 0.1 mm diameter, was found to deliver,
21.16% at 3 h, 45.41% at 6 h, 79.14% at 12 h and 96.34% at 24 h of
CBZ from the osmotic device.
The optimum formulation showed also that zero order had
the higher regression value compared to the first and Higuchi
kinetics in the following order; R20 (0.9917); R
2
1 (0.8902); R
2
HTable 5 e ANOVA analysis and PC% for each factor in the OAD
Responses A B
p-value PC% p-value P
3 h 0.016 11.65 0.002 7
6 h 0.02 8.03 0.003 7
12 h 0.07 7.78 0.011 6
24 h 0.28 0 0.014 6
Kinetics 0.06 4.11 0.02 4(0.9668), which indicates that the release of CBZ from the
prepared EOP tablets predominantly follows zero order ki-
netics for 12 h.
Fig. 4 and the analysis of the similarity factor f2 which was
equal to 70 (greater than 50) clearly suggest the similarity
between the prepared CBZ-EOP tablets and Tegretol CR 200
tablets for the release of CBZ. Although this similarity, CBZ-
EOP formulation is expected to have an extra-advantages
because of its independent release of physiological factors
such as gastric motility and pH and hence represents an
effective therapy tool with less fluctuations in drug levelsL9 matrix.
C D
C% p-value PC% p-value PC%
3.72 0.013 14.04 1 0
3.71 0.012 17.39 1 0
6.34 0.03 22.89 1 0
0.95 0.09 10.95 1 0
2.06 0.029 21.86 1 0
Fig. 4 e Release profile from CBZ-EOP tablets and Tegretol
CR 200 tablets, (Mean ± SD, n [ 3).
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bowel diseases characterized by low intestinal pH [33] or in
cases of variation in gastric emptying rate due to different
physiological, pathological or pharmacological factors [34].4. Conclusion
Newdesignof EOP tabletwith a combined solubility enhancers
and a swellable polymer had been successfully prepared for
extended delivery of CBZ. The combination of a hydrophilic
polymer with surfactant as solubility promoter and the use of
swellable polymer as drug pushing system represent a new
and effective approach for the delivery of poorlywater-soluble
CBZ to be formulated in a simple and cost effective method as
EOP tablet. In this study,we extensively examined the effect of
each of the tablet core and coat component and its contribu-
tion to the release behavior and the optimized formulation
revealed that in order to have a good osmotic system; we have
to carefully select the swellable polymer, osmotic agent, plas-
ticizer, and SPM thickness. The optimized tablets showed
satisfactory USP limits with high similarity to the marketed
product Tegretol CR 200 and up to 80% drug release at a rate of
approximately zero order for up to 12h,which indicate that the
release pattern was independent of drug load. The results ob-
tained demonstrate the possibility of expanding the applica-
tion field of this new EOP tablets as controlled drug delivery
systems to poorly water-soluble drugs.
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